Printer Friendly

ROBERTS PHARMACEUTICAL OBTAINS EXCLUSIVE WORLDWIDE RIGHTS TO NEWLY APPROVED JOHNSON & JOHNSON ENDOCRINOLOGY DRUG

ROBERTS PHARMACEUTICAL OBTAINS EXCLUSIVE WORLDWIDE RIGHTS TO NEWLY
 APPROVED JOHNSON & JOHNSON ENDOCRINOLOGY DRUG
 EATONTOWN, N.J., April 13 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced today that it has concluded an agreement with Ortho Pharmaceutical Corporation, a Johnson & Johnson Company, in which Roberts has been granted exclusive worldwide commercial rights to Supprelin(R) (histrelin), a new endocrinology drug used to treat children. Supprelin, which has been designated an orphan drug, received a full New Drug Approval from the Food and Drug Administration in December 1991. Roberts plans a national launch in the near future for Supprelin. The terms of the agreement were not disclosed.
 Supprelin was recently approved by the FDA for the treatment of Central Precocious Puberty (CPP), a serious children's endocrine disorder in which puberty occurs at an abnormally early age, in some cases as early as 2 to 3 years of age. "In addition to their abnormally early sexual development, these children also suffer from significant psychosocial problems. In most cases, patients with CPP fail to attain normal adult height," said Roberts CEO and chairman, Dr. Robert A. Vukovich. "Supprelin delays puberty in children with CPP until such time as they are of appropriate chronological age. Thereafter, Supprelin is discontinued, puberty ensues, and the child matures normally."
 Roberts has been developing Somagard (deslorelin) to CPP, prostate cancer and endometriosis, a gynecologic disorder. "As a result of this licensing agreement," continued Vukovich, "Somagard will now be positioned for prostate cancer and endometriosis while Supprelin will be targeted for CPP." He continued, "The addition of Supprelin to our growing family of prescription pharmaceuticals accelerates our ability to enter the pediatric endocrinology market by about two years. Roberts will now enter this field immediately through the sale of Supprelin and provide cash flow for the support of our drug development programs." Supprelin will be the second endocrine drug of this class to be marketed by Roberts as Roberts recently obtained regulatory approval for the sale of Somagard in Ireland for prostate cancer.
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non-prescription pharmaceuticals in the United States and abroad.
 -0- 4/13/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX JNJ) CO: Roberts Pharmaceutical Corp.; Ortho Pharmaceutical Corp. ST: New Jersey IN: MTC SU: LIC


SM-TS -- NY045 -- 7749 04/13/92 12:12 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 13, 1992
Words:428
Previous Article:GRANITE ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER OF 1992
Next Article:EPA ISSUES ADMINISTRATIVE COMPLAINT AGAINST INK MANUFACTURING COMPANY FOR VIOLATIONS OF HAZARDOUS WASTE & UNDERGROUND STORAGE TANK REGULATIONS


Related Articles
ROBERTS PHARMACEUTICAL ACQUIRES EXCLUSIVE WORLDWIDE RIGHTS TO NEW ANALGESIC DRUG
ROBERTS PHARMACEUTICAL REPORTS CLINICAL TRAIL RESULTS FOR NEW ENDOCRINOLOGY DRUG
ROBERTS PHARMACEUTICAL OBTAINS EXCLUSIVE CANADIAN RIGHTS TO MARKET UROLOGICAL DRUG
GYNEX ANNOUNCES CONTRACEPTIVE LICENSE AGREEMENT WITH ORGANON
AGOURON AND SYNTEX TO COLLABORATE IN ARTHRITIS AND CANCER DRUG DISCOVERY
ROBERTS PHARMACEUTICAL SUBMITS NEW DRUG APPLICATION TO FDA FOR URINARY INCONTINENCE DRUG
ROBERTS PHARMACEUTICAL CORPORATION TO AWARD MARKETING RIGHTS FOR AGRELIN ANTI-PLATELET DRUG TO ITALIAN FIRM
ROBERTS PHARMACEUTICAL EXPANDS EUROPEAN DISTRIBUTION FOR AGRELIN ANTI- PLATELET DRUG THROUGH SCANDANAVIAN AGREEMENT
THE RADIOPHARMACEUTICALS DIVISION OF DUPONT MERCK ACQUIRES IMAGING AGENT FROM ORTHO PHARMACEUTICAL CORPORATION
ROBERTS PHARMACEUTICALS ACQUIRES THYROID PRESCRIPTION PHARMACEUTICAL PRODUCT DRUG LINE FROM GLAXO

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters